ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy

Peter G. Bittar, Myles S. Nickolich, Oluwatoyosi A. Onwuemene

Research output: Contribution to journalArticlepeer-review

Abstract

In the implementation of American Society for Apheresis national guidelines, the decision for therapeutic plasma exchange may be confounded by a clinical presentation that fits both a Category I and IV designation. We report the case of a 45-year-old female who presented with concern for a Category IV disorder, gemcitabine-induced thrombotic microangiopathy, and was ultimately diagnosed with a Category I disorder, idiopathic thrombotic thrombocytopenic purpura. This case highlights the importance of ruling out idiopathic TTP by a thorough evaluation for ADAMTS13 activity and inhibitor, even when an alternate thrombotic microangiopathy diagnosis may be likely.

Original languageEnglish (US)
Pages (from-to)423-426
Number of pages4
JournalJournal of Clinical Apheresis
Volume33
Issue number3
DOIs
StatePublished - Jun 2018

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy'. Together they form a unique fingerprint.

Cite this